Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Ovarian Carcinoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
96 of the ovarian carcinoma cases had been previously examined for mutations in TP53 and/or for overexpression of the TP53 protein.
|
9038623 |
1996 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
|
10880552 |
2000 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
|
7981076 |
1994 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although these pooled estimates might appear to offer support for various hypotheses regarding the role of p53 in ovarian carcinoma, the limitations inherent in these data hamper the interpretation of the significance of any of the findings.
|
12518363 |
2003 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An abundance of p53 null mutations in ovarian carcinoma.
|
8700537 |
1996 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.
|
16969087 |
2006 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
CA125 and p53 are reliable markers that are useful for differentiating both uterine serous and ovarian serous carcinoma from their most common subtypes (endometrioid type carcinoma of ovary and uterus) but so far there is no histopathologic marker that differentiates USC from OSC.
|
31165997 |
2019 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Conditional suppression of functional p53 increased p110alpha transcripts, protein levels and PI3K activity in immortalized, non-tumorigenic ovarian surface epithelial (OSE) cells, the precursors of ovarian carcinoma.
|
18270270 |
2008 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.
|
11099323 |
2000 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors.
|
16459017 |
2006 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
|
27997533 |
2016 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Germ line DNA isolated from peripheral leukocytes of 73 patients with ovarian carcinoma was screened for p53 sequence abnormalities utilizing single-strand conformation polymorphism analysis and direct PCR sequencing techniques.
|
7672703 |
1995 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro.
|
10741907 |
2000 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High-grade serous ovarian carcinoma is characterised by TP53 mutations, DNA repair defects, and genomic instability.
|
29361470 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Human OCCs harboring different TP53 HSMs were selectively resistant to microtubule stabilizers.
|
25958320 |
2015 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Identical p53 mutations were detected in the primary ovarian carcinoma and the subsequent MMMT in each case.
|
12068173 |
2002 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
|
21552211 |
2011 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, changes in O-GlcNAc homeostasis activate the wild type p53 pathway in ovarian cancer cells, and OGA inhibition has the potential as an adjuvant treatment for ovarian carcinoma.
|
27402830 |
2016 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present results are consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.
|
8630996 |
1996 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study we show that curcumin exhibited time- and dose-dependent cytotoxicity against monolayer cultures of ovarian carcinoma cell lines with differing p53 status (wild-type p53: HEY, OVCA429; mutant p53: OCC1; null p53: SKOV3).
|
19676105 |
2010 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of p53 is detected in 30-40% of ovarian carcinoma.
|
12770737 |
2003 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Influence of p53 status on the HSV-Tk/GCV-induced bystander effect in a panel of human ovarian carcinoma cell lines.
|
16050136 |
2005 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
|
26620706 |
2015 |